This review assessed the effects of biochemotherapy for treating metastatic melanoma as compared to chemotherapy. It concluded that biochemotherapy clearly improved response rates, but did not appear to translate into a survival benefit. Given several considerations, particularly the lack of validity assessment and heterogeneity, the authors' conclusions should be interpreted with caution.
Response rates (18 trial arms): There was a significant improvement in overall response rates using biochemotherapy compared to chemotherapy, OR 0.59 (95% CI: 0.49 to 0.72). However, there were no differences in overall response rates between the two biochemotherapy regimens using indirect comparison. There was no evidence of statistical heterogeneity among trials. Partial and complete response rates (and responses for both immunological subgroups) were significantly improved.
Survival (15 trial arms): Treatment with biochemotherapy showed no benefit in mortality rates compared to chemotherapy. There was evidence of heterogeneity (X 2 =0.006), but this was no longer significant when the most heterogeneous trials were removed.
Toxicity (11 trial arms): A greater number of patients receiving biochemotherapy experienced thrombocytopenia (OR 3.03, 95% CI: 2.16 to 4.25) and neutropenia/leukopenia (OR 1.71, 95% CI: 1.25 to 2.34). There was evidence of significant heterogeneity between trials.
There were no statistical differences in treatment related deaths between the two treatment groups (12 trials) [A: 9 trials].
Duration of response and progression-free survival were also reported in the review.
Authors' conclusions
Biochemotherapy clearly improved response rates in the treatment of metastatic melanoma, but this did not appear to translate into a survival benefit.
CRD commentary
The review objective was clear and was supported by appropriate inclusion criteria for participants, interventions, and study design. A comprehensive literature search was conducted using electronic databases and other appropriate sources, including a search for ongoing trials. The authors did not assess validity and reviewer error and bias cannot be ruled out for study selection. [A: The quality of all potential studies are assessed internally (usually independently by two systematic reviewers and/or statisticians), so reviewer bias is unlikely.] Appropriate methods were used to synthesise the data and investigate heterogeneity. However, analysis was somewhat limited as a number of trials did not provide sufficient data to allow analysis, and there was significant heterogeneity between trials for some outcome measures. Also, confidence intervals were wide for some trials, which reduced the reliability of the results. There were considerable differences in treatment regimens between trials, and as there was little data provided on patient characteristics, such as age and disease progression, it was unclear whether the patients were comparable. Given the above considerations, in particular the lack of validity assessment and heterogeneity, the authors' conclusions should be interpreted with caution as they may not be reliable.
Implications of the review for practice and research
Practice: The authors stated that in certain clinical settings increased response rates may be useful outcomes, but this needs to be considered along with any increase in toxicity associated with this approach.
